Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

er costs related to the development of new products and technologies.

Operating Profit increased to $3.7 million in the fourth quarter 2009 from $1.8 million in the fourth quarter 2008.  Excluding Restructuring Expenses and Strategic Alternative Costs of $3.3 million recorded in 2008, Operating Profit decreased $1.4 million quarter over quarter.  EBITDA was $9.4 million, or 16.0% of sales, compared to Adjusted EBITDA of $10.5 million, or 16.0% of sales last year.

The Provision for Income Taxes totaled $5.7 million in the fourth quarter 2009 compared to $1.1 million in the fourth quarter 2008.  Provision for Income Taxes includes a $5.3 million expense in the fourth quarter 2009 related to an ongoing audit of a European subsidiary.  The Company's effective tax rates have been and are expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits where there has been a recent history of losses, primarily in the U.S.

Net Loss for the fourth quarter 2009 was $2.8 million or $0.09 per share compared to $1.0 million or $0.03 per share in the fourth quarter 2008.  

Capital expenditures and depreciation for the fourth quarter 2009 were $2.9 million and $5.7 million compared to $7.3 million and $4.9 million in the fourth quarter 2008, respectively.  The decrease in capital expenditures is largely due to fourth quarter 2008 spending o
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix ... of common shares of Resverlogix have approved the ... Eastern Capital Limited of 5,600,000 units at a ... Placement"), each unit being comprised of one common ... aggregate proceeds of approximately CAD$15 million; and (ii) ...
(Date:6/30/2015)... , June 30, 2015  Today, Americord Registry, one ... announced Andrew Horne , a partner at Kirkland & ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... Americord,s Advisory Board," says Martin Smithmyer , CEO of ... his legal career that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... ... 2015 , ... The maximum number of shares proposed to be purchased in ... of unvested restricted stock). On June 29, 2015, the last trading day prior to ... on the OTCBB was $2.29 per share. , The tender offer will expire on ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... participant in its Phase 1/2 clinical trial of ... unilateral Achilles tendinosis, has been enrolled and their ... ultrasound-guided injections. RCT-01 is comprised of non-bulbar dermal ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... Campbell Alliance, the leading management consulting firm specializing in ... launched a new practice area focused on medical affairs. ... practice enables the firm to specifically target the evolving needs ... firm has done work in the area of medical affairs ...
... OSLO, Norway, June 17 , ... Improve Remission Rates and,Reduce Short-Term Mortality Compared to Previous ... (OSE: CLAVIS) today announces positive final results,from a Phase ... in patients with late-stage acute myeloid leukaemia (AML). In ...
... Nearly 200 Quantitative Immunoassays for Discovery and Validation ... Texas, June 17 Rules-Based Medicine, Incorporated (RBM), ... announced the availability of the most comprehensive collection ... efficacy and efficiency in drug and diagnostic development. ...
Cached Biology Technology:Campbell Alliance Launches New Practice Area Focused on Medical Affairs 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... NEW YORK -- Water vapor and clouds are the ... atmosphere-ocean climate modeling study shows that the planet,s temperature ... The study, conducted by Andrew Lacis and ... in New York, examined the nature of Earth,s greenhouse ...
... University of British Columbia today welcomed the announcement of ... Health Research (CIHR) and Genome British Columbia for research ... led by UBC researchers Brett Finlay and Deborah Money, ... today in Toronto by federal Health Minister Leona Aglukkaq. ...
... Cancer Research congratulates 12 of its members on their election ... new members and five foreign associates. Considered among ... the award recognizes individuals who have demonstrated outstanding professional achievement ... medicine. "This is a great day for cancer ...
Cached Biology News:Carbon dioxide controls Earth's temperature 2Carbon dioxide controls Earth's temperature 3The AACR congratulates its members elected to the Institute of Medicine 2
... Acid Resistant SpeedVac Model SPD131DDA , ... The SPD131DDA is designed to handle the rigors ... new slim design, digital display, dual independent timers, ... coated chamber and vapor pathway. , , ...
...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
Biology Products: